*Actual vial appearance, contents, and dosage may vary and is based on your prescription.

GLP-1/ GIP

GLP-1/GIP therapy is based on dual incretin signaling, targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These hormones play complementary roles in appetite regulation, glucose metabolism, and insulin signaling. Dual-agonist therapies are designed to support metabolic balance by influencing hunger signaling, gastric emptying, and glucose-dependent insulin activity under licensed provider supervision. (Physiology overview: https://pubmed.ncbi.nlm.nih.gov/20852371/)

Free Shipping

Medical Consultation Included

$ 215 Per Month

$ 645 Full Price

Start Your Plan

Available in 48 states (excluding Alabama and Mississippi)
No hidden membership, consultation, or shipping costs
Care reviewed by a licensed provider in your state
Prescription issued only when clinically appropriate

Insulin Support

Metabolic Balance

Appetite Control

Educational only; outcomes are not guaranteed.

Supports Appetite & Satiety Regulation

GLP-1 and GIP receptors are involved in central and peripheral pathways that regulate hunger, fullness, and eating behavior.
https://pubmed.ncbi.nlm.nih.gov/20181806/

Supports Glucose & Insulin Signaling Pathways

Dual incretin signaling supports glucose-dependent insulin secretion and glucagon regulation, contributing to metabolic homeostasis.
https://pubmed.ncbi.nlm.nih.gov/20852371/

Supports Body Weight Regulation Pathways

GLP-1/GIP dual-agonist therapies have been studied in large randomized clinical trials evaluating body weight regulation in adults with overweight or obesity.
https://pubmed.ncbi.nlm.nih.gov/35658024/

Supports Cardiometabolic Health Markers

Clinical trials have evaluated dual incretin therapies for effects on cardiometabolic risk markers in specific populations.
https://pubmed.ncbi.nlm.nih.gov/35306410/

Supports Long-Term Metabolic Wellness

Sustained incretin signaling, combined with nutrition and lifestyle support, has been associated with ongoing metabolic regulation in long-term studies.
https://pubmed.ncbi.nlm.nih.gov/36805426/

Initial 3-month care period
Designed to support continuity, monitoring, and consistency of care
Ongoing care options available following the initial period, with the ability to manage or discontinue thereafter

Clinical review typically completed within 24 hours
Pharmacy processing may take 2–7 business days, depending on availability
Once dispensed, medication is shipped via 2-day delivery

Prescriptions are issued by licensed healthcare providers based on an individual clinical evaluation and medical eligibility. Compounded medications are not FDA-approved, and their safety and effectiveness have not been independently evaluated by the FDA.

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.

Important Note:

Information provided is for educational purposes only and does not constitute medical advice. All care and prescriptions are provided solely at the discretion of a licensed healthcare provider following an individual evaluation.

Mechanisms of Incretin Hormones (GLP-1 & GIP)

Drucker DJ. — Incretin biology and metabolic regulation.

SURMOUNT-1 Trial — Tirzepatide and Body Weight Regulation

Jastreboff AM, et al. New England Journal of Medicine (2022).

SURPASS Clinical Program — Dual GLP-1/GIP Agonism

Frias JP, et al. — Glycemic and metabolic outcomes.

Cardiometabolic Outcomes With GLP-1/GIP Therapy

Sattar N, et al. — Review of cardiometabolic effects.

Physiology of GLP-1 and Appetite Regulation

Holst JJ. — GLP-1 receptor signaling and satiety.

Long-Term Outcomes of Incretin-Based Therapies

Rubino D, et al. — Extended metabolic outcomes.

NIH / NIDDK — Incretin-Based Therapies Overview

GLP 1 + B12

I appreciated how everything was explained clearly, step by step, from the very beginning. The process never felt rushed or confusing, and there was no pressure at any point. Instead, the guidance helped me understand my options and feel comfortable moving forward at my own pace.

A Celara Med User

GLP 1 + B12

A Celara Med User

GLP-1/GIP therapy targets two incretin pathways instead of one, supporting appetite regulation and glucose metabolism through complementary receptor mechanisms.
https://pubmed.ncbi.nlm.nih.gov/35658024/

No. GLP-1/GIP therapies do not replace insulin. They work through incretin signaling that influences insulin secretion in a glucose-dependent manner.
https://pubmed.ncbi.nlm.nih.gov/20852371/

Adults seeking support for metabolic health, appetite regulation, or weight-management pathways may be evaluated by a licensed healthcare provider. Eligibility is determined through individual clinical review.

Individuals complete a medical intake reviewed by a licensed provider. A prescription is issued only if clinically appropriate.

Some individuals may experience gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, or reduced appetite, particularly during dose escalation. Side effects vary and should be discussed with a provider.

GLP-1/GIP therapies are typically administered via subcutaneous injection on a scheduled basis, as directed by the prescribing provider.

Yes. Dual incretin therapy is commonly paired with nutrition guidance, lifestyle support, and coaching as part of a comprehensive care plan, when approved by a provider.

GLP-1/GIP therapy through Celara Med is available in 48 states, excluding Alabama and Mississippi, subject to state regulations and provider licensure.

Yes. GLP-1/GIP therapy is offered within a structured care plan designed for continuity, monitoring, and appropriate clinical oversight.